Spero Therapeutics pivots to immunology | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded19 Aug 2026

Publisherfeeds.acast.com ↗

Handlerec:20070400

Show notes

Spero Therapeutics just hit a major milestone with FDA approval of Utebzi, the first oral carbapenem antibiotic for complicated UTIs — a breakthrough after years of development alongside GSK. But the company’s big move is ahead: it’s pivoting to immune-mediated diseases, hiring top immunology expert Dr. Debra Zack as CMO, and securing $105 million in non-dilutive funding tied to Utebzi royalties. They’re advancing SP001, a CD40 ligand inhibitor targeting IgG4-RD, with Phase Two trials set for Q2 2027 — positioning Spero for a bold new era in immunology. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/b8d2c7f239977872

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.